ATE224187T1 - Verfahren zur vorbeugung und behandlung des myokardialen stunnings - Google Patents

Verfahren zur vorbeugung und behandlung des myokardialen stunnings

Info

Publication number
ATE224187T1
ATE224187T1 AT98959929T AT98959929T ATE224187T1 AT E224187 T1 ATE224187 T1 AT E224187T1 AT 98959929 T AT98959929 T AT 98959929T AT 98959929 T AT98959929 T AT 98959929T AT E224187 T1 ATE224187 T1 AT E224187T1
Authority
AT
Austria
Prior art keywords
preventing
phospholamban
treating myocardial
myocardial stunning
stunning
Prior art date
Application number
AT98959929T
Other languages
English (en)
Inventor
Heimo Haikala
Petri Kaheinen
Jouko Levijoki
Juha Kaivola
Martti Ovaska
Jarmo Pystynen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of ATE224187T1 publication Critical patent/ATE224187T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Soil Working Implements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Road Signs Or Road Markings (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Quinoline Compounds (AREA)
  • Processing Of Meat And Fish (AREA)
  • Fertilizers (AREA)
AT98959929T 1997-12-12 1998-12-11 Verfahren zur vorbeugung und behandlung des myokardialen stunnings ATE224187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99014697A 1997-12-12 1997-12-12
PCT/FI1998/000976 WO1999030696A1 (en) 1997-12-12 1998-12-11 A method for the prevention and treatment of stunned myocardium

Publications (1)

Publication Number Publication Date
ATE224187T1 true ATE224187T1 (de) 2002-10-15

Family

ID=25535825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959929T ATE224187T1 (de) 1997-12-12 1998-12-11 Verfahren zur vorbeugung und behandlung des myokardialen stunnings

Country Status (13)

Country Link
US (1) US5968959A (de)
EP (1) EP1039884B1 (de)
JP (1) JP2002508314A (de)
AT (1) ATE224187T1 (de)
AU (1) AU1565599A (de)
BR (1) BR9813549A (de)
CA (1) CA2311932A1 (de)
DE (1) DE69808131T2 (de)
DK (1) DK1039884T3 (de)
ES (1) ES2184341T3 (de)
PT (1) PT1039884E (de)
WO (1) WO1999030696A1 (de)
ZA (1) ZA9811180B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
EP1728516A1 (de) * 1998-11-02 2006-12-06 The Regents of the University of California Methode zur Hemmung der Phospholamban Aktivität zur Behandlung von Herzkrankheiten und Herzversagen
EP1126866B1 (de) * 1998-11-02 2007-02-07 The Regents of The University of California Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
JP2002062296A (ja) * 2000-08-22 2002-02-28 Yamaguchi Technology Licensing Organization Ltd 心不全治療薬のスクリーニング方法
ATE423574T1 (de) 2000-09-11 2009-03-15 Univ California Dominant-negativer plb mutant zur behandlung der herzerkrankungen
AU2003265663A1 (en) * 2002-08-23 2004-03-11 University Of Connecticut Keto cannabinoids with therapeutic indications
WO2005023292A1 (en) * 2003-09-03 2005-03-17 The General Hospital Corporation Methods of treating restenosis
AR055041A1 (es) * 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
FR2970964B1 (fr) * 2011-01-28 2013-12-13 Univ Claude Bernard Lyon Nouveaux derives d'azacoumarines presentant une activite inhibitrice des pompes mdr
US9334256B2 (en) * 2011-06-15 2016-05-10 Nono Inc. Agents and methods for treating ischemic and other diseases
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
US11730729B2 (en) 2020-07-20 2023-08-22 Neurodon Corporation Quinolines that modulate SERCA and their use for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259635A (en) * 1962-07-26 1966-07-05 Cassella Farbwerke Mainkur Ag 7-hydroxy coumarin derivative
US3515721A (en) * 1967-06-26 1970-06-02 Cassella Farbwerke Mainkur Ag 3-tertiary-aminoethyl-4-methyl or phenyl-7-ethoxycarbonylmethoxy - halo or mononitro coumarins and congeners
IT1088554B (it) * 1977-11-17 1985-06-10 F I D I A Spa Procedimento sellettivo per la preparazione di derivati della 7-indrossi cumarina
IT1160365B (it) * 1978-12-19 1987-03-11 F I D I A Spa Applicazioni in campo farmacologico e terapeutico dell'8-cloro-3-(beta-dietilamincetil)-4-metil-7-etossi-carbonilmetossicumarina cloridrato preparato allo stato puro mediante procedimento selettivo, con particolare riguardo alla sua azione antiaritmica
WO1999000132A1 (en) * 1997-06-25 1999-01-07 Orion Corporation Use of phospholamban inhibitors for increasing coronary flow

Also Published As

Publication number Publication date
PT1039884E (pt) 2003-01-31
EP1039884B1 (de) 2002-09-18
CA2311932A1 (en) 1999-06-24
ZA9811180B (en) 1999-06-09
DK1039884T3 (da) 2002-12-09
US5968959A (en) 1999-10-19
AU1565599A (en) 1999-07-05
BR9813549A (pt) 2000-10-10
EP1039884A1 (de) 2000-10-04
ES2184341T3 (es) 2003-04-01
DE69808131T2 (de) 2003-06-05
JP2002508314A (ja) 2002-03-19
DE69808131D1 (de) 2002-10-24
WO1999030696A1 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
ATE224187T1 (de) Verfahren zur vorbeugung und behandlung des myokardialen stunnings
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE154758T1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
EP0742718A4 (de) Verfahen zurHemmung von Angiogenese und Tumorwachstum und zur Behandlung von Ophtalmologischen Beschwerden mit Angiostatischen und Therapeutischen Steroiden
WO1994000095A3 (en) Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
DE69728245D1 (de) System zur mechanischen Behandlung des Herzflimmerns
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
ATE209483T1 (de) Behandlung von multipler sklerose
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ID29187A (id) Terapi kombinasi alfa internferon-ribavirin untuk memusnahkan hcv-rna yang dapat ditemukan pada pasien-pasien yang mengalami infeksi hepatitis c kronis
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
DE60127552D1 (de) Intrakorporelle medikamente zur hoch-energetischen phototherapeutischen behandlung von krankheiten
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
DE69622989D1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE50008353D1 (de) Zahnschleifkörper zur behandlung eines engstandes von zähnen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1039884

Country of ref document: EP

REN Ceased due to non-payment of the annual fee